Publications | Page 90 | Pathology & Laboratory Medicine

Filter By Faculty

Filter by Principal Investigator

2021

Peters TL, Patil T, Le AT, Davies KD, Brzeskiewicz PM, Nijmeh H, et al. Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC. NPJ Precis Oncol. 2021;5(1):91.

Khosravi P, Lysandrou M, Eljalby M, Li Q, Kazemi E, Zisimopoulos P, et al. A Deep Learning Approach to Diagnostic Classification of Prostate Cancer Using Pathology-Radiology Fusion. J Magn Reson Imaging. 2021;54(2):462-471.

Yang HS, Shemesh A, Li J, Xie T, Apple FS, Williams JA, et al. No increase in the incidence of cardiac troponin I concentration above the 99th percentile by Siemens Centaur high-sensitivity compared to the contemporary assay. Clin Biochem. 2021;89:77-80.

Schwartz DA, Baldewijns M, Benachi A, Bugatti M, Bulfamante G, Cheng K, et al. Hofbauer Cells and COVID-19 in Pregnancy. Arch Pathol Lab Med. 2021;145(11):1328-1340.

Chan A, Carniello JV, Gao Q, Sigler A, Baik J, Roshal M, et al. Role of Flow Cytometric Immunophenotyping for Classic Hodgkin Lymphoma in Small Biopsy and Cytology Specimens. Arch Pathol Lab Med. 2021.

Ke Q, Dinalankara W, Younes L, Geman D, Marchionni L. Efficient representations of tumor diversity with paired DNA-RNA aberrations. PLoS Comput Biol. 2021;17(6):e1008944.

Mukhopadhyay C, Yang C, Xu L, Liu D, Wang Y, Huang D, et al. G3BP1 inhibits Cul3SPOP to amplify AR signaling and promote prostate cancer. Nat Commun. 2021;12(1):6662.

Bhalla S, Bakouny Z, Schmidt AL, Labaki C, Steinharter JA, Tremblay DA, et al. Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study. Lung Cancer. 2021;160:78-83.

Rana HQ, Koeller DR, Schwartz A, Manning DK, Schneider KA, Krajewski KM, et al. Pathogenicity of VHL variants in families with non-syndromic von Hippel-Lindau phenotypes: An integrated evaluation of germline and somatic genomic results. Eur J Med Genet. 2021;64(12):104359.

Zhou L, Huang X, Niesvizky R, Pu Z, Xu G. Caspase-8 Regulates the Antimyeloma Activity of Bortezomib and Lenalidomide. J Pharmacol Exp Ther. 2021;379(3):303-309.